Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
1
20%
Ph phase_3
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Withdrawn2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)

Trials by Status

completed240%
withdrawn240%
active_not_recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

NCT02726386
completedphase_1

Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

NCT01486628
completedphase_1

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

NCT02604914
withdrawnphase_3

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

NCT02782481
withdrawnphase_3

A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

NCT03462043

Clinical Trials (5)

Showing 5 of 5 trials
NCT02726386Phase 2

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

Active Not Recruiting
NCT01486628Phase 1

Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

Completed
NCT02604914Phase 1

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

Completed
NCT02782481Phase 3

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Withdrawn
NCT03462043Phase 3

A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
5